Kestra Medical Technologies (NASDAQ:KMTS) CFO Vaseem Mahboob Sells 8,817 Shares of Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) CFO Vaseem Mahboob sold 8,817 shares of Kestra Medical Technologies stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $22.61, for a total value of $199,352.37. Following the completion of the transaction, the chief financial officer owned 99,282 shares in the company, valued at $2,244,766.02. This trade represents a 8.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Vaseem Mahboob also recently made the following trade(s):

• On Monday, August 3rd, Vaseem Mahboob sold 5,391 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $23.80, for a total value of $128,305.80.
• On Thursday, July 30th, Vaseem Mahboob sold 3,980 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.75, for a total transaction of $90,545.00.

Kestra Medical Technologies Stock Performance

Kestra Medical Technologies stock traded up $1.16 during trading hours on Monday, reaching $23.99. 373,728 shares of the stock were exchanged, compared to its average volume of 404,856. Kestra Medical Technologies, Ltd. has a 52-week low of $14.10 and a 52-week high of $30.00. The stock has a market cap of $1.41 billion, a P/E ratio of -9.91 and a beta of 0.58. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.41 and a current ratio of 4.41. The firm’s 50 day moving average is $22.62 and its 200 day moving average is $22.48.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The firm had revenue of $28.64 million for the quarter. Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%. Analysts predict that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. BTIG Research boosted their target price on shares of Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Wolfe Research set a $30.00 price target on Kestra Medical Technologies in a research note on Wednesday, July 15th. Oppenheimer began coverage on Kestra Medical Technologies in a research note on Tuesday, July 21st. They issued a “market perform” rating for the company. Wall Street Zen cut Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Finally, The Goldman Sachs Group decreased their price objective on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $27.83.

Institutional Trading of Kestra Medical Technologies

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KMTS. Price T Rowe Associates Inc. MD raised its stake in Kestra Medical Technologies by 137.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company’s stock valued at $115,878,000 after purchasing an additional 2,529,851 shares during the last quarter. Brown Advisory Inc. boosted its stake in shares of Kestra Medical Technologies by 34.1% during the 4th quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock worth $44,775,000 after purchasing an additional 428,996 shares during the last quarter. Alliancebernstein L.P. grew its holdings in shares of Kestra Medical Technologies by 13.7% during the third quarter. Alliancebernstein L.P. now owns 1,491,970 shares of the company’s stock worth $35,449,000 after buying an additional 179,885 shares in the last quarter. Eventide Asset Management LLC raised its position in shares of Kestra Medical Technologies by 5.4% in the fourth quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock valued at $33,671,000 after buying an additional 65,288 shares during the last quarter. Finally, Franklin Resources Inc. lifted its stake in shares of Kestra Medical Technologies by 180.8% during the fourth quarter. Franklin Resources Inc. now owns 951,008 shares of the company’s stock valued at $25,221,000 after buying an additional 612,343 shares during the period.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.